Interventional × Neoplasms, Glandular and Epithelial × Paclitaxel × Clear all
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
NCT01523678 2019-07-10

Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers

Belgian Gynaecological Oncology Group

Phase 2 Completed
108 enrolled